Bliss GVS Pharma shareholding: Promoters 35.01% in 2026

Overview of the latest ownership snapshot

Bliss GVS Pharma Ltd.’s shareholding data for the quarter ended June 2026 shows promoters holding 35.01% of the company. In the same quarter, foreign institutional investors (FIIs) held 8.07% and retail and other investors together accounted for 47.45%. The disclosure also shows “other domestic institutions” at 9.21% and mutual funds at 0.26%. These numbers matter because they frame who controls the company, how concentrated ownership is, and whether institutional participation is rising or falling.

The reported splits in the provided data include multiple category break-ups, including one that lists insurance and mutual funds separately, and another that groups “other domestic institutions.” Some figures are also presented as approximate in filings (for example, promoters at 35%, DIIs at 9.4%, and FIIs at 8.1% for the June 2026 quarter). Readers should treat the June 2026 quarter table as the cleanest quarter-on-quarter comparison because it provides the same categories across Sep 2025, Dec 2025, Mar 2026, and Jun 2026.

Shareholding pattern for Jun 2026 (as disclosed)

For the quarter ended June 2026, the category-wise ownership is presented as promoters, foreign institutions (FII), other domestic institutions, retail and other, and mutual funds. Promoters stood at 35.01%, down from 35.36% in March 2026. FIIs stood at 8.07% in June 2026, compared with 10.45% in March 2026 and 14.54% in December 2025. Retail and other investors stood at 47.45% in June 2026.

The same quarter-end snapshot includes mutual funds at 0.26%. “Other domestic institutions” is shown at 9.21% for June 2026. This provides a useful lens into how the institutional and non-institutional mix has shifted over the last four reported quarters.

Quarter-on-quarter change: Sep 2025 to Jun 2026

The quarter comparison provided indicates notable movement in FII ownership over the four quarters shown. FIIs reduced from 13.27% in Sep 2025 to 8.07% in Jun 2026, based on the quarter table. Over the same period, retail and other investors moved from 45.36% in Sep 2025 to 47.45% in Jun 2026, with a spike to 49.15% in Mar 2026. Promoter holding stayed in a narrow band around the mid-35% range.

Other domestic institutions increased to 9.21% in Jun 2026 from 5.04% in Mar 2026, as per the same table. Mutual funds show 0.26% in Jun 2026, while earlier quarters in that table show dashes for mutual funds. The figures highlight that the biggest visible shift in the four-quarter view is the reduction in FII share.

Longer-term promoter holding trend (Mar 2021 to Jun 2026)

The time series provided for promoters shows a gradual rise over multiple years. Promoter holding is shown at 33.31% in Mar 2021 and ends at 35.01% in Jun 2026. Between mid-2022 and 2023, promoter holding moved above 34% and later crossed 35% in Mar 2023 (35.04%) and stayed near that level through 2025 and early 2026.

This longer series helps separate short-term quarter-to-quarter changes from a broader ownership direction. Even though June 2026 is slightly lower than March 2026 in the quarter table, it still reflects a higher promoter stake versus the early-2021 levels shown.

Share price and market snapshot mentioned in the data

A price reference in the supplied data states that as of 6 June 2025 at 10:01 AM, Bliss GVS Pharma traded at ₹739.9 on NSE and ₹740.1 on BSE. Separately, a market screen snapshot lists BLISSGVS at an LTP of ₹685.10 with a -2.02% change. The same snapshot shows market capitalisation at ₹7,280.92 crore for that screen.

Another market cap figure provided is ₹7,405.23 crore. Since multiple market snapshots are cited without a single timestamp for each, these values should be read as point-in-time references from different moments in the provided inputs.

Key data table: Jun 2026 shareholding and recent comparison

Corporate development: proposed acquisition and open offer trigger

The provided information also references a major corporate development from May 2026. The company disclosed that certain promoter and non-promoter shareholders entered into a Share Purchase Agreement (SPA) with Anupam Rasayan India Ltd. The proposed acquisition was for approximately 43.28% of Bliss GVS Pharma’s paid-up equity share capital, for Rs. 1,369 crore, subject to regulatory approvals and other closing conditions.

The same disclosure notes that the transaction triggered a mandatory open offer for up to an additional 26% stake from public shareholders. In addition, the company confirmed that no decision had been finalised by promoters and advised investors to rely only on official disclosures to avoid false market sentiment.

Financial snapshot from the peer screen (with unit normalisation)

A market screen table in the inputs provides a financial snapshot for BLISSGVS. It lists total income at 23,034.67 lakhs and net profit at 3,861.77 lakhs. Normalised to a single base unit, that is total income of ₹230.35 crore and net profit of ₹38.62 crore. The same screen lists EPS at ₹3.65, P/E at 51.84, and promoter holdings at 35.01%.

These figures are presented as part of a comparable market screen alongside other pharma names, but the supplied data does not specify the financial period for those income and profit figures. As a result, they should be treated as the values shown in the screen rather than attributed to a specific quarter or year.

Why the ownership mix matters for investors

With promoters at 35.01% and retail and other investors at 47.45% in Jun 2026, the company has a large non-institutional ownership base. That mix can influence trading behaviour, particularly around corporate developments like the May 2026 SPA disclosure and the related open offer trigger. The quarter table also shows FIIs reducing their stake over the past four quarters shown, from 13.27% in Sep 2025 to 8.07% in Jun 2026.

At the same time, other domestic institutions increased to 9.21% in Jun 2026 from 5.04% in Mar 2026 in the same table. Investors typically track these shifts because they may change the shareholder base’s stability and voting dynamics, especially when a potential change-of-control transaction is under discussion.

Conclusion

Bliss GVS Pharma’s June 2026 shareholding snapshot shows promoters at 35.01%, FIIs at 8.07%, other domestic institutions at 9.21%, retail and other at 47.45%, and mutual funds at 0.26%. The longer-term series indicates promoter holding has risen from 33.31% in Mar 2021 to 35.01% in Jun 2026. Alongside the ownership data, the May 2026 disclosure of an SPA for a proposed 43.28% acquisition and a related open offer for up to 26% adds a key corporate context, with the company asking investors to rely only on official disclosures as the process remains subject to approvals and closing conditions.